Haemonetics Corporation
NYSE:HAEMedical - Instruments & Supplies
+$0.84 today
- Market cap
- $5.59B
- Beta
- 0.54
- P/E (TTM)
- 34.9
- EPS (TTM)
- $2.11
Volume 0.48M
Average 0.88M
HAE Common Stock Repurchased
Cash spent buying back the company's own shares.
Haemonetics CorporationNYSE: HAE
Common Stock Repurchased · Q1 FY2027 · quarter ended Jun 2026
Common stock repurchased turns negative
Q1 FY2027 common stock repurchased was -$3.5M, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was -$178.5M. Over 3 fiscal years it compounded at +32.6% a year.
Context
- Common stock repurchased amounted to 13.1% of revenue in FY2026, down 3.4 pp from a year earlier.
- Common stock repurchased increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly common stock repurchased holds near -$3.5M or moves back toward the trailing-twelve-month quarterly average of -$44.63M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Repurchased history
USD · from the cash flow
- Latest · FY2026
- (175M) USD
- Year-over-year change
- +22.2%
| Period | Period end | Common Stock Repurchased | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-28 | (175M) | +22.2% |
| FY2025 | 2025-03-29 | (225M) | — |
| FY2024 | 2024-03-31 | 0 | +100.0% |
| FY2023 | 2023-03-31 | (75M) | — |
| FY2022 | 2022-03-31 | 0 | — |
Common Stock Repurchased vs competitors
How HAE compares with its peers on the latest reported figures
- HAE's LTM Jun 2026 common stock repurchased of $178.5M is the largest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +19.0% is the lowest of 7, against a peer median of +196.7%.
- Common stock repurchased amounts to 13.2% of revenue for HAE, versus a peer median of 0.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $178.5M | +19.0% | +32.6% | 13.2% | |
| LTM Jul 2026 | $100.01M | +487.6% | +157.5% | 5.4% | |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | $60.6M | +293.5% | -8.3% | 2.6% |
| LTM Mar 2026 | $39.87M | — | +54.2% | 6.7% | |
| LTM Jun 2026 | $10.6M | — | — | 1.2% | |
| LTM Mar 2026 | $601K | +7612.5% | — | 0.2% | |
| LTM Jun 2026 | $0 | +100.0% | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | +100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | +100.0% | — | 0.0% | |
| Peer median (excluding HAE) | $0 | +196.7% | +54.2% | 0.2% | |
Competitors are the stored peer set for HAE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | 43.38M | 115.4M | 117.56M | 167.68M | 97.31M |
| Depreciation & Amortization | 97.75M | 93.31M | 97.22M | 115.59M | 111.72M |
| Deferred Income Tax | 5.01M | 4.78M | (1.01M) | (15.7M) | (714K) |
| Stock-Based Compensation | 24.36M | 25.58M | 28.33M | 29.64M | 33.83M |
| Change in Working Capital | (15.18M) | 25.5M | (63.07M) | (91.98M) | (23.65M) |
| Accounts Receivables | (34.97M) | (24.42M) | (24.19M) | 6.96M | (14.88M) |
| Inventory | 24.31M | 30.75M | (60.06M) | (64.7M) | 47.36M |
| Accounts Payables | 0 | 39.82M | 0 | 0 | (16.57M) |
| Other Working Capital | (4.51M) | (20.65M) | 21.19M | (34.24M) | (39.56M) |
| Other Non-Cash Items | 16.95M | 8.48M | 2.73M | (23.49M) | 74.74M |
| Operating Cash Flow | 172.26M | 273.06M | 181.75M | 181.73M | 293.22M |
| Capital Expenditures | (96.51M) | (110.19M) | (38.13M) | (39.28M) | (32.78M) |
| Acquisitions (Net) | 8.14M | (2M) | (242.35M) | (107.62M) | 1.38M |
| Purchases of Investments | 0 | (33.21M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 2.02M | 1.61M | (41.91M) | (15M) | (87.96M) |
| Investing Cash Flow | (86.35M) | (143.79M) | (322.39M) | (161.9M) | (179.55M) |
| Debt Repayment | (17.5M) | (9.63M) | 37.75M | 447.31M | (6.25M) |
| Common Stock Issued | 6.55M | 0 | 1.33M | (1.91M) | 7.89M |
| Common Stock Repurchased | 0 | (75M) | 0 | (225M) | (175M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (4.8M) | (15.74M) | (922K) | (111.58M) | (5.1M) |
| Financing Cash Flow | (15.75M) | (100.36M) | 38.16M | 108.82M | (178.46M) |
| Effect of Forex Changes | (2.98M) | (3.94M) | (3.19M) | (685K) | 3.46M |
| Net Change in Cash | 67.19M | 24.97M | (105.67M) | 127.96M | (61.32M) |
| Free Cash Flow | 75.75M | 162.87M | 143.63M | 142.45M | 260.44M |
Haemonetics Corporation
NYSE:HAE
Intrinsic Alpha fair value
Locked
Current Price
$122.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.